SEC Form 3 · accession 0001711454-17-000003

Xenetic Biosciences, Inc. · XBIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

10% Owner

Period of report

Jan 23, 2014

Accepted (ET)

Oct 27, 2017 · 8:24 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001534525

Table I — non-derivative securities

Security	Date	Code	Shares	A/D	Owned after	D/I	Nature of ownership
Common Stock	holding	—	—	—	4,544,488	D
Series B Preferred Stock	holding	—	—	—	1,454,545	D
Common Stock	holding	—	—	—	821,567	I	By LLC SynBio, its wholly-owned subsidiary
Series A Preferred Stock	holding	—	—	—	970,000	I	By LLC SynBio, its wholly-owned subsidiary

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrants^F1	—	holding	—	—	—	Jul 1, 2015	Jul 1, 2020	Common Stock	606,062	—	D
Warrants^F1	—	holding	—	—	—	Mar 31, 2016	Mar 31, 2021	Common Stock	353,540	—	D
Warrants^F1	—	holding	—	—	—	Jul 1, 2016	Jul 1, 2021	Common Stock	50,506	—	D
Warrants	$4.95	holding	—	—	—	Aug 26, 2016	Aug 26, 2021	Common Stock	17,980	—	D
Warrants	$4.95	holding	—	—	—	Sep 9, 2016	Sep 9, 2021	Common Stock	32,526	—	D
Class B Warrants^F2	$4.00	holding	—	—	—	Nov 7, 2016	Nov 7, 2021	Common Stock	1,454,545	—	D
Warrants^F3	$25.41	holding	—	—	—	Dec 31, 2014	Dec 30, 2019	Common Stock	204,394	—	I

F1Warrants are exercisable at the lesser of (i) $6.60 per share and (ii) 120% of the price per share of Xenetic Biosciences, Inc. common stock paid in its next occurring capital raise with a value of at least $7,000,000. Warrants were granted at six various dates in Q1 2016.
F2The Reporting Person owns Class B Warrants exercisable into 1,454,545 shares of Common Stock. The exercise of such Class B Warrants is limited by the beneficial ownership limitation included in such Class B Warrants, which provides that such Class B Warrants may not be exercised if the holder thereof would own more than 4.99% of the outstanding Common Stock of the Issuer as after giving effect to such exercise. The amount of shares of Common Stock into which such Class B Warrants are exercisable was calculated for the purposes of this report without giving effect to any ownership limitation of the Reporting Person.
F3The Reporting Person's wholly owned subsidiary, LLC SynBio, owns warrants exercisable into 204,394 shares of Common Stock. Such warrants are subject to performance vesting. The vesting milestones need to be achieved by December 31, 2017 (50%) and July 31, 2018 (50%). The amount of shares of Common Stock into which such warrants are exercisable was calculated for the purposes of this report without giving effect to any performance vesting limitations.